Bryan Frantz
Optometrist · Brunswick, OHNPI 1063934271
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 26 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by AbbVie at 36.9% of the total. 2025 is the largest year on record at $213, more than ten times the $12 reported in 2019. That places this record below the midpoint for optometrist clinicians in OH, where the typical reported total is $701.
Across 26 payments — averaging $26.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$250
- Coopervision Inc.$98
- Johnson & Johnson Vision Care, Inc.$75
- Carl Zeiss Meditec, Inc.$68
- Oyster Point Pharma, Inc.$48
- Glaukos Corporation$40
- plus $97 from 4 others
What the payments were for
- Food & beverage$676100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 7 | $250 |
| Coopervision Inc. | 5 | $98 |
| Johnson & Johnson Vision Care, Inc. | 4 | $75 |
| Carl Zeiss Meditec, Inc. | 1 | $68 |
| Oyster Point Pharma, Inc. | 3 | $48 |
| Glaukos Corporation | 2 | $40 |
| Tarsus Pharmaceuticals, Inc. | 1 | $31 |
| Mallinckrodt Hospital Products Inc. | 1 | $24 |
| Bausch & Lomb Americas Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $20 |
How this compares
$676 in reported general payments places this provider in the 45th percentile of 1,995 optometrist providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Brimonidine Tartrate | 16 | $3,197 |
| Latanoprost | 164 | $2,756 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 22 | $705 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 30 | $627 |
| Ketorolac Tromethamine | 11 | $384 |
| Timolol Maleate | 60 | $378 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 19 | $191 |
| ErythromycinErythromycin Base | 11 | $120 |
Paid to pharmacies, not to this prescriber.
Other optometrist in Brunswick
- Mile BrujicBowling Green$1.3M
- Gregory DenaeyerColumbus$846K
- Cory LappinMontgomery$367K
- Chris SmileyColumbus$305K
- Thomas ChesterCleveland$300K
- Carly RoseCincinnati$203K
- Wendy HallierReynoldsburg$200K
- John LahrCincinnati$145K
- Erin RueffColumbus$131K
- Mary YackeyCincinnati$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.